aspirin has been researched along with ramipril in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.08) | 18.2507 |
| 2000's | 14 (29.17) | 29.6817 |
| 2010's | 27 (56.25) | 24.3611 |
| 2020's | 6 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ehring, T; Heusch, G; Rose, J; Sakka, SG; Skyschally, A | 1 |
| Weinsaft, JW | 1 |
| Isles, CG; Paterson, JR | 1 |
| Ball, SG; Castaigne, AD; Commerford, PJ; Distiller, L; Fisher, BM; Gonzalez-Jaunatey, J; Kennedy, J; Mogensen, CE; Nosadini, R; Novials, A; Ostergren, J; Palma-Gámiz, J; Perrone-Filardi, P; Schipperheijn, JJ; Senges, J; Trevisan, R | 1 |
| Bergmann, JF; Caulin, C; Cohen-Solal, A; Habib, A; Jondeau, G; Kevorkian, JP; Knellwolf, AL; Lebret, M; Levy, B; Mahé, I; Meune, C; Mourad, JJ; Simoneau, G | 1 |
| Schröder, S | 1 |
| Bosch, J; Gerstein, HC; Lonn, E; McQueen, MJ; Yusuf, S | 1 |
| Bermas, B; Costenbader, KH; de Pablo, P; Finckh, A; Gall, V; Karlson, EW; Liang, MH; Lynch, M; Schur, PH | 1 |
| Bauriedel, G; Lüderitz, B; Nickenig, G; Schneider-Schmitt, M; Skowasch, D; Viktor, A | 1 |
| Afzal, R; Pais, P; Pogue, J; Sigamani, A; Xavier, D; Yusuf, S | 1 |
| Afzal, R; Eikelboom, J; Gupta, R; Mohan, V; Pais, P; Sigamani, A; Teo, K; Thomas, N; Xavier, D; Yusuf, S | 1 |
| Accardo, S; Americo, L; Castello, A; Cicero, S; Sarullo, FM; Schicchi, R; Schirò, M | 1 |
| Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T | 1 |
| Sankar, AS; Venkappaya, D; Vetrichelvan, T | 1 |
| Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO | 1 |
| Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Vinereanu, D | 1 |
| Afzal, R; Gao, P; Pais, P; Sigamani, A; Teo, KK; Xavier, D; Yusuf, S | 1 |
| Bautista, LE; Casas, JP; Chirinos, JA; Ferrante, D; Ferreccio, C; Herrera, VM; Medina-Lezama, J; Miranda, JJ; Oróstegui Arenas, M; Pérez, CM; Pichardo, R; Sánchez Abanto, JR; Schapochnik, N; Silva, E; Vera-Cala, LM | 1 |
| Ambrosio, G; Ambrosioni, E; Bacchelli, S; Borghi, C; Cicero, AF; Esposti, DD; Omboni, S; Vinereanu, D; Zava, D | 1 |
| Aslam, R; Ducrocq, N; Gerard, A; Kimmoun, A; Levy, B; Perez, P; Thivilier, C | 1 |
| Alexander, MR; Burley, JC; Khaled, SA; Roberts, CJ; Yang, J | 1 |
| Ranawaka, H; Shyamali, NL | 1 |
| Barrios, V; Escobar, C | 1 |
| Castellano, JM; Fuster, V; Tamargo, J | 1 |
| Ambrosio, G; Ambrosioni, E; Borghi, C; Novo, S; Omboni, S; Vinereanu, D | 2 |
| Lozano, I; Rondan, J; Sanchez, LI; Segovia, E; Vega, B; Vegas, JM | 1 |
| Einecke, D | 1 |
| Abarca, B; González-Juanatey, JR; Llisterri, JL; Lobos, JM; Mostaza, JM | 1 |
| Stiefelhagen, P | 1 |
| Barrios, V; Castellano, JM; Cosin-Sales, J; Fuster, V; Gracia, A; Kaskens, L; Ruiz, JE; Zsolt, I | 1 |
| Cheruvu, HS; Devalapalli, MMR; Sampathi, S; Shivakumar, S; Veeravalli, VB; Yertha, T | 1 |
| Cianci, R; Di Lazzaro-Giraldi, G; Gigante, A; Proietti, M; Rosato, E; Tubani, L | 1 |
| Chouksey, D; Dani, R; Dube, M; Dubey, A | 1 |
| Gaziano, TA; Jardim, TV; Ogden, JM; Pandya, A; Rodgers, A; Sy, S; Weinstein, MC | 1 |
| González-Juanatey, JR; Oudovenko, N; Tamargo, J; Torres, F; Weisser, B | 1 |
| Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS; Serag, A | 1 |
| Alonso-Canovas, A; Chico-García, JL; Cruz-Culebras, A; de Felipe Mimbrera, A; García-Madrona, S; Gómez-López, A; Masjuan, J; Matute-Lozano, C; Natera-Villalba, E; Ros-Castelló, V; Sánchez-Sánchez, A; Vera-Lechuga, R | 1 |
| Jayswal, KV; Prajapati, PB; Shah, SA | 1 |
| Alonso Garcia, A; Andres, V; Barczi, G; Baviera, M; Beghi, E; Bejot, Y; Bhatt, DL; Bueno, H; Castellano, JM; Colivicchi, F; Collier, T; Cordero, A; Di Fusco, SA; Doehner, W; Domingo-Fernández, A; Ecarnot, F; Fernandez Alvira, JM; Fernandez Ferro, J; Fernandez-Ortiz, A; Foresta, A; Fuster, V; Ibañez, B; Kasprzak, M; Linhart, A; Lopez, N; Lozano, I; Lubanda, JC; Marin Ortuño, F; Merkely, B; Meyer, A; Ojeda-Fernandez, L; Owen, R; Perel, P; Pocock, SJ; Ponikowski, P; Proietti, M; Quesada, AJ; Rodriguez-Manero, M; Roncaglioni, MC; Sanchez, PL; Schiele, F; Schoos, MM; Simon, T; Van de Werf, F; Vazquez Rodriguez, JM; Vivas, D | 1 |
| Abdallah, NA; El-Awady, MI; El-Brashy, AM; Ibrahim, FA | 1 |
8 review(s) available for aspirin and ramipril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dietary Supplements; Female; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin; Patient Selection; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Triglycerides | 2000 |
What is the relevance of the HOPE study in general practice?
Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Family Practice; Female; Humans; Male; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Ramipril | 2001 |
[Is the supplementation with antioxidants effective in the treatment of atherosclerosis?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antioxidants; Arteriosclerosis; Ascorbic Acid; Aspirin; beta Carotene; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Free Radicals; Humans; Male; Nutritional Physiological Phenomena; Oxidative Stress; Placebos; Platelet Aggregation Inhibitors; Primary Prevention; Prospective Studies; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Tocopherols; Vitamins | 2004 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Simvastatin; Stroke | 2012 |
Improving cardiovascular protection: focus on a cardiovascular polypill.
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Platelet Aggregation Inhibitors; Ramipril; Simvastatin | 2016 |
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Ramipril; Secondary Prevention | 2015 |
Long-term antiplatelet therapy with the polypill after stenting: More information is necessary.
Topics: Aged; Aspirin; Coronary Thrombosis; Drug Administration Schedule; Drug Combinations; Humans; Male; Platelet Aggregation Inhibitors; Ramipril; Simvastatin; Stents | 2016 |
10 trial(s) available for aspirin and ramipril
| Article | Year |
|---|---|
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Female; Heart Failure; Humans; Inflammation; Kidney Diseases; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Ramipril; Stroke; Ventricular Function, Left; Vitamin E | 2005 |
Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Aspirin; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Patient Dropouts; Patient Selection; Pilot Projects; Pravastatin; Ramipril; Treatment Refusal; Vitamin B Complex | 2005 |
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Capsules; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Research Design; Secondary Prevention; Simvastatin; Treatment Outcome | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Risk Reduction Behavior; Simvastatin; Treatment Outcome | 2009 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolol; Biological Availability; Capsules; Cardiovascular Diseases; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Simvastatin; Tandem Mass Spectrometry; Young Adult | 2010 |
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Platelet Aggregation Inhibitors; Prospective Studies; Ramipril; Risk Assessment; Risk Factors; Stroke Volume; Systole; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Capsules; Cardiovascular Diseases; Cholesterol, LDL; Creatinine; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; India; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Potassium; Ramipril; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2012 |
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Captopril; Europe; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ramipril; Randomized Controlled Trials as Topic; Retrospective Studies; Ventricular Dysfunction, Left | 2013 |
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
Topics: Aspirin; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ramipril; Treatment Outcome | 2021 |
Polypill Strategy in Secondary Cardiovascular Prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Ramipril; Secondary Prevention | 2022 |
30 other study(ies) available for aspirin and ramipril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Aspirin does not prevent the attenuation of myocardial stunning by the ACE inhibitor ramiprilat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Cyclooxygenase Inhibitors; Dogs; Drug Interactions; Heart; Hemodynamics; Myocardial Stunning; Platelet Aggregation; Postmortem Changes; Ramipril; Regional Blood Flow | 1996 |
Effect of ramipril on cardiovascular events in high-risk patients.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Humans; Ramipril | 2000 |
ACE inhibitor reduces cardiovascular events by 22%.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Humans; Multicenter Studies as Topic; Myocardial Ischemia; Oximes; Piperidines; Platelet Aggregation Inhibitors; Ramipril; Randomized Controlled Trials as Topic | 2000 |
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arteries; Aspirin; Blood Pressure; Chronic Disease; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diastole; Dose-Response Relationship, Drug; Enalapril; Endpoint Determination; Female; Heart Failure; Heart Rate; Humans; Lisinopril; Male; Manometry; Middle Aged; Observer Variation; Prospective Studies; Ramipril; Renin; Reproducibility of Results; Single-Blind Method; Systole; Thromboxane B2; Time Factors; Treatment Outcome | 2003 |
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
Topics: Adenosine Diphosphate; Aged; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Clopidogrel; Collagen; Coronary Artery Disease; Electric Impedance; Enalapril; Female; Fibrinolytic Agents; Germany; Humans; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ramipril; Ticlopidine; Treatment Outcome | 2006 |
Tako-tsubo cardiomyopathy observed in a patient with sepsis and transient hyperthyroidism.
Topics: Amlodipine; Anti-Bacterial Agents; Antihypertensive Agents; Antithyroid Agents; Aspirin; Echocardiography; Electrocardiography; Female; Glucocorticoids; Humans; Hyperthyroidism; Methimazole; Middle Aged; Ofloxacin; Platelet Aggregation Inhibitors; Prednisone; Propranolol; Ramipril; Sepsis; Takotsubo Cardiomyopathy | 2009 |
Simultaneous estimation of ramipril, acetylsalicylic acid and atorvastatin calcium by chemometrics assisted UV-spectrophotometric method in capsules.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Calibration; Capsules; Chemistry, Pharmaceutical; Heptanoic Acids; Humans; Least-Squares Analysis; Models, Theoretical; Pyrroles; Ramipril; Regression Analysis; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2011 |
A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
Topics: Aged; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Developing Countries; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Latin America; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors | 2013 |
Critical illness-related corticosteroid insufficiency in cardiogenic shock.
Topics: Adrenal Insufficiency; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Bisoprolol; Critical Illness; Epinephrine; Fibrinolytic Agents; Hirudins; Humans; Hydrocortisone; Male; Peptide Fragments; Piperazines; Prasugrel Hydrochloride; Ramipril; Recombinant Proteins; Shock, Cardiogenic; Thiophenes; Treatment Outcome | 2013 |
3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles.
Topics: Aspirin; Atenolol; Delayed-Action Preparations; Drug Combinations; Drug Liberation; Excipients; Hydrochlorothiazide; Powder Diffraction; Pravastatin; Printing, Three-Dimensional; Ramipril; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; X-Ray Diffraction | 2015 |
Takotsubo cardiomyopathy after an emotional outburst.
Topics: Antihypertensive Agents; Aspirin; Carbazoles; Carvedilol; Diuretics; Echocardiography; Family Conflict; Female; Furosemide; Humans; Middle Aged; Platelet Aggregation Inhibitors; Propanolamines; Ramipril; Takotsubo Cardiomyopathy; Ventricular Dysfunction, Left | 2015 |
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Cardiovascular Diseases; Diabetic Cardiomyopathies; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Ramipril; Randomized Controlled Trials as Topic; Retrospective Studies; Systole; Ventricular Dysfunction, Left | 2016 |
[Polypill for secondary coronary heart disease prevention].
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Medication Adherence; Ramipril | 2015 |
A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Europe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ramipril; Secondary Prevention; Spain | 2016 |
[Combination drug improves adherence].
Topics: Aspirin; Atorvastatin; Capsules; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Ramipril; Secondary Prevention | 2016 |
Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Follow-Up Studies; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Markov Chains; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ramipril; Retrospective Studies; Secondary Prevention; Spain | 2017 |
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Chi-Square Distribution; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Early Medical Intervention; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Ramipril; Randomized Controlled Trials as Topic; Recovery of Function; Retrospective Studies; Risk Factors; Systole; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Hansen solubility parameters for assay method optimization of simvastatin, ramipril, atenolol, hydrochlorothiazide and aspirin in human plasma using liquid chromatography with tandem mass spectrometry.
Topics: Aspirin; Atenolol; Chromatography, Liquid; Humans; Hydrochlorothiazide; Ramipril; Reproducibility of Results; Simvastatin; Solubility; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2017 |
Heart rate variability in nephrotic syndrome: Role of sympathetic and parasympathetic system.
Topics: Aged; Aspirin; Electrocardiography, Ambulatory; Heart Rate; Humans; Male; Nephrotic Syndrome; Ramipril; Sympathetic Nervous System | 2018 |
Twenty-and-a-half syndrome: a case report.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Brain; Brain Ischemia; Cranial Nerve Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Middle Aged; Paresis; Physical Therapy Modalities; Platelet Aggregation Inhibitors; Ramipril; Stroke; Syndrome | 2019 |
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Topics: Adrenergic beta-Antagonists; Aspirin; Atenolol; Budgets; Cardiovascular Diseases; Cost Savings; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Medication Adherence; Middle Aged; Nutrition Surveys; Platelet Aggregation Inhibitors; Ramipril; Renin-Angiotensin System; Secondary Prevention; Stroke; United States | 2019 |
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.
Topics: Algorithms; Aspirin; Atenolol; Capsules; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Least-Squares Analysis; Ramipril; Simvastatin; Spectrophotometry, Ultraviolet | 2020 |
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cerebrovascular Disorders; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Recurrence; Retrospective Studies; Secondary Prevention; Tablets; Tertiary Care Centers; Time Factors; Treatment Outcome | 2020 |
Estimation of Multiple Fixed-Dose Combination Products of Ramipril and Aspirin by GERV-Chromatography Using DoE and Risk-Based Enhanced Analytical Quality by Design Approach.
Topics: Aspirin; Chromatography, High Pressure Liquid; Ramipril; Research Design | 2021 |
Multicomponent spectrophotometric determination of a ternary mixture of widely-prescribed cardiovascular drugs by four different methods.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Humans; Ramipril; Spectrophotometry | 2023 |